Literature DB >> 10582686

Decreased insulin-like growth factor-II/mannose 6-phosphate receptor expression enhances tumorigenicity in JEG-3 cells.

D B O'Gorman1, M Costello, J Weiss, S M Firth, C D Scott.   

Abstract

The insulin-like growth factor-II/mannose-6 phosphate receptor (IGF-II/M6PR) is believed to bind and degrade the potent mitogen IGF-II, a growth factor for many tumors. This receptor has been shown to be mutated and/or lost in a significant percentage of a variety of tumors, implying that it may act as a negative regulator of cell growth. In this study, we demonstrate that down-regulation of this receptor, mediated by antisense IGF-II/M6PR cDNA transfection into JEG-3 choriocarcinoma cells, results in increased growth rate in vitro and increased tumor growth rate in vivo. These findings demonstrate that a decrease in IGF-II/M6PR expression results in a growth advantage in JEG-3 cells and are consistent with the hypothesis that the IGF-II/M6PR is an inhibitor of tumor growth.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10582686

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer.

Authors:  Jodi L Kreiling; Michelle A Montgomery; Joseph R Wheeler; Jennifer L Kopanic; Christopher M Connelly; Megan E Zavorka; Jenna L Allison; Richard G Macdonald
Journal:  FEBS J       Date:  2012-07-02       Impact factor: 5.542

Review 2.  Heterotrimeric G proteins and the single-transmembrane domain IGF-II/M6P receptor: functional interaction and relevance to cell signaling.

Authors:  C Hawkes; A Amritraj; R G Macdonald; J H Jhamandas; S Kar
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

Review 3.  Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.

Authors:  Mónica Enguita-Germán; Puri Fortes
Journal:  World J Hepatol       Date:  2014-10-27

4.  IGF2 actions on trophoblast in human placenta are regulated by the insulin-like growth factor 2 receptor, which can function as both a signaling and clearance receptor.

Authors:  Lynda K Harris; Ian P Crocker; Philip N Baker; John D Aplin; Melissa Westwood
Journal:  Biol Reprod       Date:  2010-10-27       Impact factor: 4.285

Review 5.  Epigenetic regulation of insulin-like growth factor axis in hepatocellular carcinoma.

Authors:  Hend Mohamed El Tayebi; Ahmed Ihab Abdelaziz
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 6.  The role of IGF-1R in pediatric malignancies.

Authors:  Su Young Kim; Jeffrey A Toretsky; Daniel Scher; Lee J Helman
Journal:  Oncologist       Date:  2009-01-06

7.  Tissue-specific inactivation of murine M6P/IGF2R.

Authors:  Andrew A Wylie; David J Pulford; Alison J McVie-Wylie; Robert A Waterland; Heather K Evans; Yuan-Tsong Chen; Catherine M Nolan; Terry C Orton; Randy L Jirtle
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

8.  M6P/IGF2R modulates the invasiveness of liver cells via its capacity to bind mannose 6-phosphate residues.

Authors:  Verena Puxbaum; Elisabeth Nimmerfall; Christine Bäuerl; Nicole Taub; Pia-Maria Blaas; Johannes Wieser; Mario Mikula; Wolfgang Mikulits; Ken M Ng; George C T Yeoh; Lukas Mach
Journal:  J Hepatol       Date:  2012-04-17       Impact factor: 25.083

9.  M6P/IGF2R loss of heterozygosity in head and neck cancer associated with poor patient prognosis.

Authors:  Timothy A Jamieson; David M Brizel; J Keith Killian; Yoshihiko Oka; Hong-Seok Jang; Xiaolong Fu; Robert W Clough; Robin T Vollmer; Mitchell S Anscher; Randy L Jirtle
Journal:  BMC Cancer       Date:  2003-02-13       Impact factor: 4.430

10.  Decreased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells.

Authors:  Zhihong Chen; Yinlin Ge; Natalie Landman; Jing X Kang
Journal:  BMC Cancer       Date:  2002-07-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.